Clinical Trial Update: Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial (CORT-X) evaluating CORT108297 to attenuate effects of acute stress in the allocortex; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Memory Impairment

Drugs mentioned

• CORT108297

Snippet

Sponsor: Johns Hopkins University | Conditions: Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Status: RECRUITING